생검 기기 세계 시장 규모는 2024년 28억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장 규모가 46억 달러에 달할 것으로 예상하며, 2025년부터 2033년까지 5.47%의 연평균 성장률(CAGR)을 보일 것으로 전망하고 있습니다. 암 발병률 증가, 맞춤형 의료에 대한 선호도 증가, 환자의 편안함과 회복 시간 단축을 위한 최소침습적 시술의 추진은 시장을 이끄는 주요 요인 중 일부입니다.
생검 기기는 진단 목적으로 환자의 체내에서 조직 샘플을 채취하기 위해 특별히 고안된 의료기기입니다. 다양한 의료 현장에서 널리 사용되고 있으며, 암, 감염성 질환, 염증성 질환 등 다양한 질환의 진단에 도움을 주고 있습니다. 바늘 생검 기기, 집게 생검 기기, 진공 보조 생검 기기 등 다양한 유형이 있으며, 각 유형은 특정 의료 요구에 따라 다릅니다. 초음파, CT 스캔, MRI와 같은 실시간 영상 진단 기술을 사용하여 의료 전문가는 조직을 채취해야 할 위치를 정확하게 파악할 수 있어 시술의 성공률을 높일 수 있습니다. 그 결과, 생검 기기는 현대 진단 의료에 필수적인 도구로 큰 지지를 받고 있으며, 정확하고 시기적절한 개입을 용이하게 하고 있습니다.
진단을 위해 생검이 필요한 질병에 걸리기 쉬운 고령화 사회는 예측 기간 동안 시장 성장을 촉진할 것입니다. 또한, 맞춤형 의료에 대한 관심이 높아짐에 따라 질병의 진행을 모니터링하고 그에 따라 치료 계획을 조정하기 위해 여러 번의 생검이 필요한 경우가 많기 때문에 생검 기기의 사용 빈도가 증가할 것입니다. 이에 따라 환자의 편안함과 회복 시간 단축을 목표로 하는 최소침습적 시술의 세계적 추진으로 인해 이러한 최소침습적 시술용으로 설계된 생검 기기의 채택이 가속화되고 있습니다. 또한, 일부 국가의 의료비 지출 증가와 지원적인 상환 정책이 시장 성장에 기여하고 있습니다. 전 세계 정부 및 민간 보험사들이 더 나은 의료 서비스를 제공하기 위해 노력함에 따라 생검과 같은 진단 절차에 대한 상환 가능성이 높아져 환자가 더 쉽게 이용할 수 있게 되어 시장 성장을 촉진하고 있습니다.
암 발병률 상승
전 세계 암 발병률의 증가는 생검 기기 시장의 중요한 동인입니다. 암의 진단은 최적의 치료를 위해 정확하고 빠른 진단이 필요하며, 생검은 필수적인 진단 도구가 되고 있습니다. 세계보건기구(WHO)에 따르면, 암은 세계 제2의 사망 원인으로 2018년 기준 960만 명이 사망한 것으로 추정됩니다. 암 발생률이 계속 증가함에 따라 정확하고 효율적인 진단 방법의 필요성이 높아지고 있습니다. 따라서 생검 기기는 악성 조직을 식별하고 임상의가 적절한 치료 계획을 세울 수 있도록 하는 데 필수적인 역할을 하고 있습니다. 암 발병률의 증가는 고급 생검 기기에 대한 수요를 불러일으키며 시장 성장에 긍정적인 영향을 미치고 있습니다.
급속한 기술 발전
생검 기기의 기술 혁신은 또 다른 큰 성장 촉진요인입니다. 기술의 발전은 생검 절차의 효과, 속도 및 안전성을 향상시키고 있습니다. 예를 들어, 진공 보조 생검 기기는 조직 샘플을 더 빠르고 편안하게 추출할 수 있어 환자 경험을 개선하고 있습니다. 또한 초음파, CT 스캔, MRI와 같은 실시간 영상 진단 기술을 생검 기기에 통합함으로써 의사는 보다 정확한 표적 부위를 얻을 수 있고, 시술 합병증을 줄이고 진단의 신뢰성을 높일 수 있습니다. 이러한 기술적 강화는 의료 전문가들의 제품 채택률 향상에 기여하고 있으며, 이는 시장 성장을 촉진하고 있습니다.
헬스케어 인프라에 대한 대규모 투자
신흥국을 중심으로 헬스케어 인프라에 대한 투자가 증가하고 있는 것도 시장 성장을 견인하고 있습니다. 공공 및 민간 기관의 자금 지원 증가는 진단 실험실 및 첨단 의료기기 구매를 포함한 의료 시설의 현대화를 촉진하고 있습니다. 전 세계적으로 의료 시스템이 보다 정확하고 시기적절한 진단을 제공하는 데 초점을 맞추고 있기 때문에 첨단 생검 기기의 도입은 자연스러운 흐름이 되고 있습니다. 이는 환자들에게 양질의 진단 기술에 대한 폭넓은 접근성을 보장하는 동시에 이러한 장비의 시장을 확대하여 시장 성장에 긍정적인 동력을 제공하고 있습니다.
The global biopsy devices market size reached USD 2.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.6 Billion by 2033, exhibiting a growth rate (CAGR) of 5.47% during 2025-2033. The rising prevalence of cancer, increasing preference for personalized medicine, and the push toward minimally invasive procedures for patient comfort and quicker recovery times are some of the major factors propelling the market.
Biopsy devices are medical instruments specifically designed for extracting tissue samples from a patient's body for diagnostic purposes. They are widely used in various healthcare settings and are instrumental in diagnosing a wide range of conditions, including cancer, infections, and inflammatory diseases. They are available in different types, such as needle, forceps, and vacuum-assisted biopsy devices, each serving particular medical requirements. By employing real-time imaging techniques like ultrasound, CT scans, or MRI, healthcare professionals can pinpoint the exact location from which the tissue needs to be taken, thereby improving the procedure's success rate. As a result, biopsy devices have gained immense traction as indispensable tools in modern diagnostic medicine, facilitating precise and timely interventions.
The aging population, which is more susceptible to diseases requiring biopsy for diagnosis, will stimulate market growth during the forecast period. Additionally, the heightened focus on personalized medicine, which often necessitates multiple biopsy procedures to monitor the disease's progression and adapt the treatment plan accordingly, increases the frequency of biopsy device usage. In line with this, the global push toward minimally invasive procedures for patient comfort and quicker recovery times has accelerated the adoption of biopsy devices designed for these less intrusive techniques. Furthermore, the rising healthcare expenditure and supportive reimbursement policies in several countries are contributing to market growth. As governments and private insurers across the globe aim to provide better healthcare services, there is a higher likelihood of reimbursements for diagnostic procedures like biopsies, making them more accessible to patients fueling the market growth.
Rising Incidence of Cancer
The increasing burden of cancer worldwide is a significant driver for the biopsy devices market. Cancer diagnoses require precise and early-stage identification for optimal treatment, making biopsies an essential diagnostic tool. According to the World Health Organization, cancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018. As cancer rates continue to escalate, there has been a rise in the need for accurate and efficient diagnostic methods. Therefore, biopsy devices are becoming vital in identifying malignant tissues, allowing clinicians to formulate appropriate treatment plans. The rising incidence of cancer catalyzes the demand for advanced biopsy devices, thus positively influencing market growth.
Rapid Technological Advancements
Innovations in biopsy devices represent another major growth-inducing factor. Technological advancements are improving the efficacy, speed, and safety of biopsy procedures. For instance, vacuum-assisted biopsy devices allow quicker and more comfortable extraction of tissue samples, thereby enhancing patient experience. Additionally, the integration of real-time imaging techniques such as ultrasound, CT scans, or MRI with biopsy devices provides physicians with a more accurate target area, reducing procedural complications and increasing diagnostic reliability. Such technological enhancements contribute to higher product adoption rates among healthcare professionals, which in turn is propelling market growth.
Extensive Investments in Healthcare Infrastructure
The rising investments in healthcare infrastructure, especially in emerging economies, also drive the market toward growth. The increased funding by public and private agencies facilitates the modernization of medical facilities, including diagnostic labs and the acquisition of state-of-the-art medical equipment. As healthcare systems globally are focusing on delivering more accurate and timely diagnostics, the incorporation of advanced biopsy devices becomes a natural progression. This has expanded the market for these devices while ensuring broader access to high-quality diagnostic procedures for patients, thus providing a positive thrust to the market growth.
Surgical biopsy dominates the market
Surgical biopsy is widely preferred among healthcare professionals for accurate and comprehensive tissue analysis due to its high diagnostic accuracy and versatility. Unlike other biopsy methods, such as needle or liquid biopsies, surgical biopsies enable the removal of an entire tumor or a larger section of tissue, providing a more comprehensive sample for analysis. This increased sample size enhances the ability of pathologists to make accurate and definitive diagnoses, particularly in complex cases where malignancy is suspected but not confirmed through less invasive methods. Additionally, surgical biopsies are often employed in locations difficult to access by needle-based techniques, such as deeper tissues or organs. Another major contributing aspect is its utility beyond diagnosis; it often serves as both a diagnostic and therapeutic procedure by allowing for the complete excision of small malignant masses. The surgical approach is also favored in cases requiring immediate intervention or when other biopsy methods have yielded inconclusive results, thus supporting the segment growth.
Biopsy guidance systems represent the most popular product
Biopsy guidance systems are crucial in enhancing the accuracy and efficiency of biopsy procedures. These guidance systems often integrate with imaging technologies like ultrasound, MRI, or CT scans to provide real-time visualization of the tissue area being targeted. Such integration allows healthcare professionals to precisely locate and assess the tissue sample needed for diagnosis, thereby reducing the risk of complications and procedural errors. In a medical landscape where precision is paramount, these guidance systems offer a significant edge. Their utility is especially prominent in complex cases where the targeted tissue is located deep within the body or near critical organs, where pinpoint accuracy is essential. Moreover, guidance systems are becoming increasingly user-friendly and compatible with various types of biopsy devices, which promotes their adoption across different healthcare settings. By facilitating quicker, more accurate, and safer procedures, biopsy guidance systems are indispensable tools that clinicians rely on, which is fueling the segment growth.
Breast biopsy accounts for the majority of the market share
The main factor driving the growth of this segment is the high incidence of breast cancer globally. According to the World Cancer Research Fund, breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. Early detection is critical for effective treatment, and biopsy remains one of the most reliable diagnostic methods for confirming the presence or absence of cancerous cells in breast tissue. Furthermore, advances in imaging technologies such as mammography and ultrasound have significantly improved the accuracy of breast biopsies, making it a preferred diagnostic option. Public awareness campaigns about the importance of early detection have also played a role in the frequent utilization of breast biopsy procedures. Increasingly, women are becoming proactive about their breast health, leading to more screenings and, subsequently, more biopsies to confirm or rule out malignancy. As a result, the breast biopsy segment continues to maintain its leading position in the biopsy devices market.
Ultrasound guided biopsy holds the largest share in the market
Ultrasound-guided biopsy provides real-time imaging, allowing healthcare professionals to visualize the exact area from which the tissue sample is to be extracted. This enhances the accuracy and efficiency of the biopsy procedure. Moreover, ultrasound-guided biopsies are less invasive and generally quicker than other methods, requiring only local anesthesia. This further improves patient comfort and reduces recovery time. Compared to other imaging modalities like MRI or CT scans, ultrasound is considerably less expensive and more widely available across healthcare settings, including smaller clinics and outpatient centers. This accessibility makes it a go-to option for many physicians. Besides this, ultrasound does not involve exposure to ionizing radiation, making it a safer alternative for repeated procedures and specific patient populations, such as pregnant women. Due to these advantages-real-time imaging, cost-effectiveness, minimal invasiveness, and safety-ultrasound-guided biopsy is widely preferred, contributing to segment growth.
Hospitals and clinics are often the first point of contact for patients requiring diagnostic procedures, including biopsies. These healthcare settings are equipped with advanced diagnostic tools and skilled professionals capable of performing a wide range of biopsy types. The growing incidence of diseases requiring biopsies, coupled with the expansion of healthcare infrastructure globally, has led to higher adoption of biopsy devices in these institutions. Moreover, hospitals often have the financial capacity to invest in the latest biopsy technologies, further augmenting the market growth.
Although smaller in market share compared to hospitals and clinics, academic and research institutes are an essential segment. These institutions primarily focus on research and development activities aimed at improving biopsy technologies or devising new diagnostic methods. They may also conduct clinical trials to evaluate the efficacy of new biopsy devices. While the volume of biopsies performed may be lower compared to hospitals, their influence on product innovation and validation is significant.
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region has a high prevalence of lifestyle-related diseases, including cancer, necessitating frequent utilization of biopsy procedures for diagnosis and monitoring. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases were diagnosed in the United States alone. In addition, North America boasts a highly developed healthcare infrastructure, including hospitals and clinics equipped with advanced diagnostic technologies, thereby facilitating the adoption of state-of-the-art biopsy devices.
Apart from this, the region has significant investments in healthcare research and development, often leading the way in medical innovation, including the development of new and more effective biopsy techniques and devices. Furthermore, there is a strong insurance framework supporting medical procedures, including biopsies, which makes these diagnostic tests more accessible to a broader population. Also, high levels of public awareness about the importance of early diagnosis and preventive healthcare catalyze the demand for diagnostic procedures such as biopsies. These combined factors position North America as the leading regional market for biopsy devices.
The market is experiencing steady growth as key players are actively engaged in a range of strategic activities aimed at consolidating their market position. These actions include the development of technologically advanced devices, such as vacuum-assisted and image-guided biopsy systems, to increase accuracy and patient comfort. Companies are also focusing on mergers, acquisitions, and strategic collaborations to expand their product portfolios and geographic reach. Additionally, significant investment is being made in research and development (R&D) to innovate new products and improve existing ones. Regulatory approvals and patent filings are other critical areas of focus aimed at securing exclusivity for innovative devices. Through these combined efforts, key market players are shaping the trajectory of the biopsy devices industry.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include: